Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 27;13(9):1313.
doi: 10.3390/jpm13091313.

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer

Shipra Gandhi  1
Affiliations
Editorial

Novel Biomarkers to Guide Immunotherapy De-Escalation in the Neoadjuvant Setting in Triple-Negative Breast Cancer

Shipra Gandhi. J Pers Med. .

Abstract

Triple-negative breast cancer (TNBC) has the highest incidence of disease recurrence and distant metastases among breast cancer subtypes, leading to significant rates of morbidity and mortality [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Rugo H.S., Olopade O.I., DeMichele A., Yau C., van’t Veer L.J., Buxton M.B., Hogarth M., Hylton N.M., Paoloni M., Perlmutter J., et al. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N. Engl. J. Med. 2016;375:23–34. doi: 10.1056/NEJMoa1513749. - DOI - PMC - PubMed
    1. Santonja A., Sanchez-Munoz A., Lluch A., Chica-Parrado M.R., Albanell J., Chacon J.I., Antolin S., Jerez J.M., de la Haba J., de Luque V., et al. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. Oncotarget. 2018;9:26406–26416. doi: 10.18632/oncotarget.25413. - DOI - PMC - PubMed
    1. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8. - DOI - PubMed
    1. Schmid P., Cortes J., Dent R., Pusztai L., McArthur H., Kummel S., Bergh J., Denkert C., Park Y.H., Hui R., et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2022;386:556–567. doi: 10.1056/NEJMoa2112651. - DOI - PubMed
    1. Schmid P., Cortes J., Dent R., Pusztai L., McArthur H., Kümmel S., Bergh J., Denkert C., Park Y.H., Hui R., et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann. Oncol. 2021;32:1198–1200. doi: 10.1016/j.annonc.2021.06.014. - DOI

Publication types

LinkOut - more resources